To cite this paper use one of the standards below:
INTRODUCTION Leukaemia is a malignant tumor which has a worldwide prevalence, with 437,033 new cases diagnosed in 2018 (1). There are many types of leukaemia, with different hematopoietic origins and disease progression. Withanolides are C-28 ergostane steroids commonly found in Solanaceae species and are known to have antitumor activity (2). OBJECTIVE: To evaluate the effects of FAR2019001 and FAR2019002 treatment on a panel of leukaemia cell lines. METHODS Cell lines: K562, K562/Lucena (chronic myelogenous leukaemia), Jurkat (acute T cell leukaemia), THP-1 (acute monocytic leukaemia) and MOLT-4 (acute lymphoblastic leukaemia) were cultured in RPMI 1640, supplemented with 10% FBS, 1µM pyruvate, 100U/L penicillin and 0.1mg/mL streptomycin. Cellular cytotoxicity MTT assay: Cells were seeded to 96-well plates twenty-four hours before treatment with samples (0.01 to 100 µM). After 48h, MTT was added and plate maintained in a CO2 incubator for 4h. After the incubation time, the supernatant was aspirated and formazan crystals solubilized with DMSO (100 µl). Absorbance was measured at 540 nm wavelength in a microplate reader. Determination of apoptosis/necrosis (Annexin V/propidium iodide): Apoptosis status was determined, by flow cytometry, 24 hours after treatment using Annexin V-Alexa Fluor 488 assay Kit (Molecular Probes). Determination of caspase activity (FLICA): The caspase activity, in single cell level, was determined by flow cytometry, 24 hours after treatment using the Vybrant FAM caspases 3 and 7 assay Kit (Molecular Probes). RESULTS Two natural metabolites isolated from a Solanaceae species were characterized and evaluated on the proliferation of leukaemia cells. We have observed that both compounds were active, inhibiting cellular growth. FAR2019002 proved to be more active at inhibiting cell growth, with IC50 values lower than its counterpart FAR2019001 in all cell lines. FAR2019001 was more active on Jurkat cells, while FAR2019002 was more active on MOLT-4 and Jurkat cells. Among the cell lines tested, Jurkat was the most sensitive cell line to the treatment with withanolides. On the other hand, K562/Lucena was resistant to the treatment with both compounds, with a higher IC50, probably due to the multidrug resistance profile with increased MDR1 gene expression. Caspase and apoptosis studies were performed using the susceptible Jurkat cell line. To better understand the mechanisms behind this activity, we treated Jurkat cells with withanolides in a concentration equivalent of IC50 and two times the IC50: 2.5 and 5 µM for FAR2019001 and 1.5 and 3 µM for FAR2019002. In Caspase assay, FAR2019002 (3µM) was more active, with 69.20% of caspase 3/7+ cells, when compared to FAR2019001 (58.55% caspase 3/7+ cells), with consequent increased numbers of apoptotic cells at 24 hours. In agreement with caspase 3/7 assay, we have observed more late apoptotic cells after FAR2019002 treatment (2xIC50; 22.00%) in comparison with FAR2019001 (2xIC50; 14.52%). CONCLUSION & PERSPECTIVES The withanolides compounds showed great antileukaemic potential, via caspase-dependent apoptosis. To better understand the mechanism underpinning this activity, we plan on unveiling apoptosis- and survival-related genes and proteins modulated by withanolides treatment.
FINANCIAL SUPPORT PROEP Farmanguinhos/CNPq 407849/2017-3.
REFERENCES (1) https://www.wcrf.org/dietandcancer/cancer-trends/worldwide-cancer-data; last access: 10/09/2019. (2) HUSSAIN, Hidayat et al. Recent patents on anti-cancer drug discovery, v. 13, n. 4, p. 411, 2018.
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper